The Centers for Medicare & Medicaid Services (CMS) has finalized sweeping changes to Medicare Advantage (MA) and Part D prescription drug programs for 2026, implementing reforms that will affect approximately 31 million seniors and disabled Americans enrolled in these plans. www.cms.gov The Contract Year 2026 final rule, released April 4, 2025, modernizes program operations while introducing new protections for dual-eligible beneficiaries and tightening oversight of plan practices.

Key Provisions Taking Effect

Holding Plans Accountable for Approved Decisions

In a significant consumer protection measure, CMS is restricting Medicare Advantage plans' ability to reopen and modify previously approved inpatient admission decisions based on information gathered after approval. [[94]] Under the new rule, plans may only reopen an approved admission for obvious error or fraud—a major shift from current practices where retrospective denials have left patients with unexpected medical bills.

"The goal of this provision is to ensure that if a plan approves an inpatient admission, it will have to honor the prior authorization," CMS stated in the final rule fact sheet. [[94]] This change addresses long-standing complaints from physicians and patients about plans approving care initially, then denying payment after services are rendered.

Closing Appeals Loopholes

CMS is taking decisive action to close MA appeals loopholes that have adversely affected both providers and enrollees. The final rule clarifies that "organization determinations"—decisions subject to MA appeal and notification requirements—include concurrent decisions made while enrollees are receiving services. [[94]]

This clarification ensures that MA appeals rules apply to adverse plan decisions regardless of whether they occur before, after, or during service delivery. Additionally, CMS is codifying requirements for plans to notify providers of coverage decisions when the provider submits requests on behalf of enrollees, not just notifying the enrollee.

Medicare Prescription Payment Plan Enhancements

Building on the 2025 implementation of the Medicare Prescription Payment Plan (MPPP), CMS is finalizing requirements for automatic election renewal beginning in 2026. [[94]] Under this system, Part D enrollees' participation in the monthly payment program will automatically extend to the next calendar year unless they opt out.

The MPPP allows Medicare beneficiaries to pay their out-of-pocket prescription drug costs through monthly installments rather than lump sums at the pharmacy—a crucial cash flow management tool for seniors on fixed incomes. CMS received numerous comments requesting streamlined renewal processes to prevent beneficiaries from losing this benefit due to administrative oversights.

Inflation Reduction Act Implementation

The final rule codifies several Inflation Reduction Act (IRA) provisions whose program instruction authority expires at the end of 2025:

Vaccine Cost Sharing Elimination

Effective for plan years beginning on or after January 1, 2023, but now formally codified for 2026 and beyond, Medicare Part D enrollees face no cost-sharing for adult vaccines recommended by the Advisory Committee on Immunization Practices (ACIP). [[94]] The Part D deductible also does not apply to these preventive services, removing financial barriers to vaccination.

Insulin Cost Cap

CMS is finalizing the $35 monthly cap on insulin cost-sharing for Part D enrollees. [[94]] For 2026, the applicable cost-sharing amount is the lesser of: $35; 25% of the maximum fair price established under the Medicare Drug Price Negotiation Program; or 25% of the negotiated price.

This provision provides critical relief for the millions of Medicare beneficiaries managing diabetes, a condition affecting approximately 29% of Medicare enrollees.

Medicare Drug Price Negotiation Program Integration

The final rule establishes distinct Prescription Drug Event (PDE) submission requirements for drugs selected under the Medicare Drug Price Negotiation Program. [[94]] Part D sponsors must submit initial PDE records within seven calendar days of receiving claims for these selected drugs—significantly faster than the standard 30-day timeframe for other medications.

CMS is also requiring that Part D sponsors' network pharmacy agreements mandate enrollment in the Medicare Transaction Facilitator Data Module (MTF DM). This ensures accurate claims processing and beneficiary access to negotiated maximum fair prices.

Dual Eligible Special Needs Plans (D-SNPs) Reforms

CMS is finalizing new federal requirements for certain D-SNPs to improve care coordination for the 12 million Americans dually eligible for Medicare and Medicaid:

• Integrated ID Cards: By 2027, D-SNPs must issue integrated member identification cards serving as ID for both Medicare and Medicaid plans [[94]]
• Unified Health Risk Assessments: Plans must conduct integrated HRAs covering both Medicare and Medicaid benefits, replacing separate assessments [[94]]
• Standardized Timeframes: CMS is codifying requirements for all Special Needs Plans (SNPs) to conduct HRAs and develop individualized care plans within specified timeframes [[94]]

These changes address fragmentation in care delivery that has long plagued dually eligible beneficiaries, who often struggle to navigate two separate insurance programs with different rules, providers, and coverage policies.

Star Ratings and Quality Measures

The final rule includes modifications to the Star Ratings program that affect how plans are evaluated and compensated. CMS is adding three new improvement activities, modifying seven existing activities, and removing eight activities from the Quality Payment Program. [[42]]

These adjustments reflect evolving priorities in healthcare quality measurement, with increased emphasis on health equity, patient experience, and outcomes-based metrics rather than process measures.

Payment Updates

CMS approved an average payment increase of 5.06% for Medicare Advantage plans for 2026. [[39]] This update reflects statutory requirements for adjusting MA capitation rates based on Medicare Fee-for-Service spending growth.

However, the maximum out-of-pocket (MOOP) limit for in-network services under MA plans will decrease to $9,250 in 2026, down from $9,350 in 2025. [[95]] This modest reduction provides additional financial protection for beneficiaries facing serious illness or injury.

Artificial Intelligence Guardrails

Notably, CMS announced it is not finalizing the proposed provision on "Ensuring Equitable Access to Medicare Advantage Services—Guardrails for Artificial Intelligence" at this time. [[94]] The agency may address AI governance in future rulemaking as the technology rapidly evolves and more evidence becomes available on appropriate safeguards.

This decision reflects CMS's cautious approach to regulating AI use in coverage determinations and care management, balancing innovation potential with patient safety concerns.

Non-Allowable Supplemental Benefits

The rule establishes guardrails for Special Supplemental Benefits for the Chronically Ill (SSBCI) by codifying a list of non-allowable examples. [[94]] Plans cannot use SSBCI funds for: non-healthy food, alcohol, tobacco products, or life insurance.

SSBCI benefits can be offered non-uniformly to qualifying MA enrollees with chronic conditions and may be non-primarily health-related, but must have a reasonable expectation of improving or maintaining the enrollee's health or overall function.

Industry Response

The American Medical Association praised the appeals process improvements while expressing concerns about ongoing prior authorization burdens. "These changes bolsters some aspects of provider appeals processes in inpatient settings but creates uncertainty on several policies," noted APTA's analysis of the final rule. [[44]]

Medicare advocacy groups generally welcomed the dual eligible reforms while calling for stronger enforcement mechanisms. "Integrated ID cards and unified assessments are long overdue," said one beneficiary advocate. "But the real test will be whether CMS holds plans accountable for implementation."

Implementation Timeline

The regulations are effective June 3, 2025, with provisions applicable to coverage beginning January 1, 2026. [[38]] Plans must update their systems, train staff, and revise member communications to comply with the new requirements by the start of the 2026 plan year.

CMS will monitor implementation closely and may issue additional guidance as plans encounter operational challenges. The agency emphasized its commitment to ensuring beneficiaries experience improved access and care coordination without disruption during the transition.

For detailed information about 2026 Medicare changes, beneficiaries can access CMS's comprehensive guide or consult with their State Health Insurance Assistance Program (SHIP).

mahnoorStaff Writer

Related Articles

Why Are Medicine Prices Skyrocketing In Pakistan? The Truth Behind The New Drug Deregulation Policy

Jun 29, 2026

Pakistan's Historic New Law: Why Polio Vaccination May Soon Be Mandatory For Passports And Schools

Jun 29, 2026

Pakistan's Magic Health Card: How The Sehat Sahulat Program Is Saving Millions Of Lives

Jun 29, 2026